Company name: Biopheresis Technologies LLC
Mission statement: Based on the Company’s system of immuno-affinity blood treatment, introduce into medical practice new treatment of cancer that is effective and well tolerated, to provide for patient well being and improved long term health, while providing an above average return to our shareholders.
Type of company: Biomedical company dedicated to the development and commercialization of a novel and patented cancer treatment technology
Address: Cary, North Carolina
Phone number: (919) 604 2189
Web site: www. BiopheresisTech.com (Under Construction)
Management team: Rigdon Lentz MD, Santo J Costa, Henry Edmunds PhD
Board members: Rigdon Lentz MD, Alston Gardner, Jeffrey Muir
Investors: Current investors are private individuals and one Cancer Research Foundation; about $950,000 has been raised as of the beginning of March.
Revenues: N/A
Year established: 1995
Employees: Employees and full time consultants — 3; part time consultants and contactors – 7
